Here's Why Gilead Sciences Stock Surged 21% in a Month

Core Insights - Gilead Sciences, Inc. (GILD) shares have increased by 20.8% over the past month, significantly outperforming the industry growth of 4.5% [2] - The stock rally was primarily driven by the publication of positive results from the ASCENT-04 study in The New England Journal of Medicine [2][8] Study Results - The phase III ASCENT-04 study evaluated the combination of Gilead's Trodelvy and Merck's Keytruda in patients with untreated, inoperable locally advanced or metastatic triple-negative breast cancer (TNBC) expressing PD-L1, enrolling 443 patients [3] - The study achieved its primary endpoint, showing a 35% reduction in the risk of disease progression or death for the Trodelvy plus Keytruda combination compared to Keytruda plus chemotherapy, with median progression-free survival (PFS) of 11.2 months versus 7.8 months [4] Safety and Collaboration - The safety profile of the Trodelvy and Keytruda combination was consistent with the known safety profiles of each drug [5] - Gilead has collaborated with Merck since 2021 to evaluate Trodelvy in combination with Keytruda in the ASCENT-04 study [5] Market Potential - Trodelvy is currently approved in over 50 countries for second-line or later metastatic TNBC and in over 40 countries for certain pre-treated HR+/HER2- metastatic breast cancer patients [6] - Gilead has submitted two supplemental biologics license applications for Trodelvy's use in first-line metastatic TNBC, with potential regulatory decisions expected in 2026, which could significantly boost sales [9] Unmet Need and Future Growth - There is a significant unmet need in first-line metastatic TNBC, where existing therapies often lead to rapid disease progression and poor outcomes, presenting a substantial opportunity for differentiated treatments [10] - The efficacy data for the Trodelvy-Keytruda combination strengthens the case for a new standard of care, potentially expanding Trodelvy's market and driving long-term revenue growth [10] Ongoing Development - Trodelvy is being evaluated in multiple ongoing phase III trials across various tumor types with high Trop-2 expression, indicating its potential as a broadly applicable oncology asset [12] - The development program includes both monotherapy and combination regimens with Keytruda, targeting earlier treatment lines in TNBC and HR+/HER2-negative breast cancer, as well as lung and gynecologic cancers [12] Strategic Diversification - A potential label expansion for Trodelvy would enhance Gilead's oncology portfolio and reduce its reliance on HIV therapies, diversifying the company's revenue base [13] - Merck's Keytruda, which accounts for around 50% of its pharmaceutical sales, is also undergoing strategies to drive long-term growth [13]